I'm in the same ballpark, and do agree that if these catalysts are only weeks away - why so quiet? I try and come up with set back scenarios which are possible. The FDA might look at our data and say "looks great, i think you are ready for your P3 trial now of 3000 patients" The FDA might have told them to stop the EIND because cytodyn was complaining that they could not get enrollment fast enough and This is just the FDA's solution. I guess these are possible, but the confidence and manufacturing ramp up seem to really say this is a go.